These Cholesterol-Reducers May Save Lives. So Why Aren’t Heart Patients Getting Them?

Powerful PCSK9 inhibitors were supposed to revolutionize care for cardiac patients. But insurers and other payers balked at sky-high prices. GINA KOLATA https://ift.tt/2DOZiTD https://ift.tt/2DL1X0A The New York Times Health Repatha (Drug), Drugs (Pharmaceuticals), Health Insurance and Managed Care, Cholesterol October 2, 2018 at 12:00AM